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Development of an Efficient G-Quadruplex-Stabilised
Thrombin-Binding Aptamer Containing a Three-Carbon
Spacer Molecule
Lukas J. Aaldering,[a, b] Vasanthanathan Poongavanam,[a] Niels Langkjær,[a] N. Arul Murugan,[c]
Per Trolle Jørgensen,[a] Jesper Wengel,[a] and Rakesh N. Veedu*[a, d, e, f]
Introduction
Oligonucleotide therapies have great potential and have at-
tracted significant interest in recent years. Aptamers are a class
of short, single-stranded oligonucleotide sequences that are
able to bind target molecules with high affinity and specificity
because of their ability to adopt three-dimensional structures.
Aptamers, often termed chemical antibodies, are generally de-
veloped by an in vitro selection process called systematic evo-
lution of ligands by exponential enrichment (SELEX).[1–3] The
developed full-length aptamers can be chemically fabricated
and truncated by using predicted secondary structures to fur-
ther improve their biophysical prop-
erties.[4] The thrombin-binding apta-
mer (TBA) is one of the most studied
G-quadruplex forming aptamers.[5] It
is a 15-mer G-rich DNA oligonucleo-
tide (5’-GGTTG GTGTG GTTGG-3’,
Scheme 1) that inhibits the forma-
tion of fibrin clots by binding to
thrombin,[5c] which makes TBA a ther-
apeutically relevant anticoagulant.
However, TBA did not meet clinical
expectations during trial stages due
to suboptimal dosing profiles ; con-
sequently, development beyond phase I clinical studies was
not initiated.[6] Since then, the investigation and improvement
of TBA have been continued.[5]
X-ray crystallography and NMR spectroscopy studies re-
vealed that TBA forms a chair-shaped antiparallel G-quadru-
plex.[7–9] The structure consists of two stacked G-tetrads con-
nected through three edgewise loops: a top central TGT and
two bottom TT loops (Scheme 1). With regard to the structure
and interaction with thrombin, a number of investigations
have shown that the loop regions of TBA are crucial for throm-
bin interaction and G-quadruplex formation.[10,11] Previous
structure–activity relationship (SAR) studies revealed that loop
The thrombin-binding aptamer (TBA), which shows anticoagu-
lant properties, is one of the most studied G-quadruplex-form-
ing aptamers. In this study, we investigated the impact of dif-
ferent chemical modifications such as a three-carbon spacer
(spacer-C3), unlocked nucleic acid (UNA) and 3’-amino-modified
UNA (amino-UNA) on the structural dynamics and stability of
TBA. All three modifications were incorporated at three differ-
ent loop positions (T3, T7, T12) of the TBA G-quadruplex struc-
ture to result in a series of TBA variants and their stability was
studied by thermal denaturation; folding was studied by circu-
lar dichroism spectroscopy and thrombin clotting time. The re-
sults showed that spacer-C3 introduction at the T7 loop posi-
tion (TBA-SP7) significantly improved stability and thrombin
clotting time while maintaining a similar binding affinity as
TBA to thrombin. Detailed molecular modelling experiments
provided novel insights into the experimental observations,
further supporting the efficacy of TBA-SP7. The results of this
study could provide valuable information for future designs of
TBA analogues with superior thrombin inhibition properties.
Scheme 1. G-quadruplex
structure of the thrombin-
binding aptamer.
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residues T4, T9, T13 and G8 are critical to preserve the G-quad-
ruplex structure, and that T3, T7 and T12 are more flexible moi-
eties that are particularly involved in thrombin inhibition.[12–15]
Krauss et al. suggested that the TT loops form a pincer-like
structure that binds the protruding region of thrombin exo-
site I.[11] In addition, it was further suggested that the stability
and rigidity of TBA is important for the interaction between
the aptamer and exosite I.[16] A large number of structural
modifications have been tested to improve the activity and
stability of TBA, often resulting in decreased stability of TBA
compared to unmodified TBA.[12–14,17, 18] However, in the last
year, several studies succeeded in improving upon TBA. Paster-
nak et al. reported that the systematic introduction of a single
UNA-U nucleotide at position T3, T7 or T12 increased the ther-
modynamic stability of TBA, and the presence of unlocked
nucleic acid (UNA)-U at position 7 showed high potency with
regard to inhibition of fibrin clot formation.[14] Borbone and
colleagues reported similar results by modifying TBA at posi-
tion T7 with an acyclic pyrimidine analogue.[13] In two recent
studies, Virgilio et al. was able to improve the functionality of
TBA. In the first study, they introduced 5’-fluoro-2’-deoxyuri-
dine residues to positions T4 and T13, achieving remarkable
improvements in melting temperatures and anticoagulant ac-
tivity.[19] In the second study, they added an extra residue at
the 3’-end or at both ends of the original TBA sequence, linked
through 3’–3’ or 5’–5’ phosphodiester bonds, resulting in
strong improvements in the thermal stability of TBA.[20]
Herein, we systematically investigated the effect of three
different chemical modifications—3’-amino-modified UNA
(amino-UNA), unlocked nucleic acid (UNA) and a three-carbon
spacer (spacer-C3 ; Scheme 2)—at loop positions T3, T7 and
T12, with the goal of improving the binding interactions with
thrombin. In the amino-UNA monomer included in this study,
the 3’-OH group was replaced with a NH2 group; thus, the link-
age to the next nucleotide became a 5’–2’ internucleotide
phosphate linkage. A small library of modified TBA sequences
was synthesised (Table 1) by varying three substitutions of resi-
dues T3, T7 and T12 with amino-UNA, UNA and spacer-C3
modifications (Table 1). The sequences were tested for quadru-
plex folding by circular dichroism (CD) spectroscopy, thermal
stability of the formed structure by melting temperature (Tm)
analysis, a thrombin clotting time assay and thrombin binding
affinity analysis of the most potent aptamer candidates by bio-
layer interferometry.
Results
Physical properties and structural characterisation of
modified TBA sequences
Modified TBA sequences were characterised by CD spectrosco-
py to understand the effects of spacer-C3, amino-UNA and
UNA modifications on the overall G-quadruplex structure of
TBA (Figure 1). All spectra showed the characteristic TBA ab-
sorbance[7]—two maxima at &240 and &295 nm and a mini-
mum at &265 nm—thus suggesting the formation of antipar-
allel G-quadruplex structures by the modification of TBA loops
with spacer-C3, amino-UNA and UNA.
Next, the thermal stability of the quadruplexes formed by
the TBA derivatives were analysed by UV melting studies (Fig-
ure S1 in the Supporting Information). The results showed a
noteworthy increase (+&6 8C) in thermal stability for substitu-
tions with a spacer-C3 (TBA-SP3, TBA-SP7 and TBA-SP12), but
the TBA variants with UNA monomers (TBA-U3, TBA-U7 and
TBA-U12) showed an increase of +2 to +5 8C (Table 2 and Fig-
ure S1). However, the introduction of amino-UNA to the loops
(TBA-A3, TBA-A7 and TBA-A12) decreased the thermal stability
in comparison with the unmodified TBA (Table 2).
Biological effect of the modified TBA sequences
To investigate the ability of the modified TBA sequences to in-
hibit the enzymatic activity of thrombin and to evaluate the
impact of quadruplex thermal stability on biological potency,
Scheme 2. Structure of the three monomer modifications used in this study:
1) spacer-C3 (X) ; 2) amino-UNA (aU); and 3) UNA (uU).
Table 1. Primary library of TBA derivatives.
Modification/sequence name Sequence
TBA (reference) 5’-GGTTGGTGTGGTTGG
aUNA (aU)/(TBA-A3) 5’-GGaUTGGTGTGGTTGG
aUNA (aU)/(TBA-A7) 5’-GGTTGGaUGTGGTTGG
aUNA (aU)/(TBA-A12) 5’-GGTTGGTGTGGaUTGG
spacer-C3 (X)/(TBA-SP3) 5’-GGXTGGTGTGGTTGG
spacer-C3 (X)/(TBA-SP7) 5’-GGTTGGXGTGGTTGG
spacer-C3 (X)/(TBA-SP12) 5’-GGTTGGTGTGGXTGG
uUNA (uU)/(TBA-U3) 5’-GGuUTGGTGTGGTTGG
uUNA (uU)/(TBA-U7) 5’-GGTTGGuUGTGGTTGG
uUNA (uU)/(TBA-U12) 5’-GGTTGGTGTGGuUTGG
Modifications are shown in bold and underlined. aU: amino-UNA, X:
spacer-C3 and uU: UNA.
Figure 1. CD spectra of TBA and TBA derivatives.
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the sequences were tested in a thrombin clotting time assay
where the change in absorption, due to thrombin-induced
clotting of fibrinogen in phosphate-buffered saline (PBS), was
spectrophotometrically measured at 380 nm. The time needed
to clot 50% of the available fibrinogen (“clotting time”) was
then determined. The clotting time without aptamer interfer-
ence was (29:6) s. The majority of the modified TBA sequen-
ces showed decreased inhibitory efficiency compared to un-
modified TBA, but TBA-SP7 showed remarkably enhanced clot-
ting time (Table 2). To validate this remarkable difference of
TBA-SP7 in the clotting time assay, further investigation of the
thrombin aptamer binding affinity was investigated by biolayer
interferometry using the BLITz instrument platform (ForteBio).
However, TBA and TBA-SP7 exhibited similar affinities (1665 nm
for TBA-SP7 and 1733 nm for TBA; Figure S2).
Computational analysis
The effect of the introduction of different monomers was fur-
ther investigated by using the stochastic dynamics (SD) simula-
tions. The model for TBA (Figure 2A) shows guanine and
thymine base stacking at positions 7 and 8 in the TGT loop,
whereas the nucleobase of the thymidine residue at position 9
is not involved in the stacking and is directed upwards and
away from the G-quadruplex core. T3 and T12 adopt a pincer-
like structure.
It has been reported that the TT loops (T3 and T12) consti-
tute the thrombin-binding motifs of TBA[11] and that these
pincer-like loops bind the protruding region of thrombin exo-
site I. Therefore, we focused on the structural changes in the
pincer-like orientation of T3 and T12, as well as on T9 of the
TGT loop. On the other hand, TBA-SP7 (Figure 2B) showed
strong binding interactions at thrombin exosite I as compared
to the TBA; this is mainly due to the fact that there are more
interactions with TBA-SP7, especially at G14, in addition to G2,
T3 and T4, which are common to both TBA and TBA-SP7 ana-
logues. Noticeably, there is a unique p–p interaction between
the residue Tyr118 and T3 of TBA-SP7. These interactions
strongly stabilise the TBA-SP7 conformation compared to the
other TBA analogues designed in this study. For a better over-
view, a molecular model was used to examine conformational
changes of TBA upon incorporation of spacer-C3, amino-UNA
and UNA at positions T3, T7 and T12. Conformational changes
of various tested aptamers binding to TBA are provided in the
Supporting Information (Figure S2).
Table 3 displays the conformational changes and the results
for thrombin clotting time activity (CT50 ; the time needed to
clot 50% of the available fibrinogen). The introduction of
amino-UNA in TBA always changed the orientation of the T9
nucleobase from an upward direction to an orientation more
towards the side and away from the guanine tetrad. Addition-
ally, the pincer-like structure of the TT loops was disrupted for
the amino-UNA introduction at T3 and T12. Spacer-C3 incorpo-
ration at T3 and T12 (TBA-SP3 and TBA-SP12) resulted in the
loss of the pincer-like structure and the wild-type orientation
of T9. However, in the case of TBA-SP7, only the organisation
Table 2. Tm values and thrombin clotting times of TBA and modified TBA
sequences.
Oligonucleotide Tm DTm Thrombin D Thrombin
[8C] [8C] clotting clotting
time [s] time [s]
thrombin – – 29:6 –
TBA 49:0 – 87:11 –
TBA-A3 47:1 @2 55:8 @32
TBA-A7 42:0 @7 51:3 @36
TBA-A12 45:1 @4 45:8 @42
TBA-SP3 55:0 +6 41:7 @46
TBA-SP7 55:0 :6 168:39 :81
TBA-SP12 55:1 +6 47:10 @40
TBA-U3 51:0 +2 36:5 @51
TBA-U7 54:0 +5 51:11 @36
TBA-U12 51:0 +2 37:4 @50
Figure 2. Comparison of molecular interactions of A) TBA and B) TBA-SP7
with thrombin (maroon). The polar interactions between TBA and thrombin
are shown, and important residues that are involved in TBA binding are
highlighted.
Table 3. Structural impact of substitution, ordered by site of modifica-
tion, including orientation of T3, T7 and T12 and the impact on anti-
thrombin function compared to normal TBA.
Site Chemistry Orientation CT50
T3 T9 T12
n.a. unmodified pincer-like upwards pincer-like /
TBA
T3 aUNA pincer-like sideways interacting –
with G4
spacer-C3 nil sideways interacting —
with G4
uUNA interacting sideways interacting —
with G4 with G4
T7 aUNA pincer-like sideways pincer-like –
spacer-C3 pincer-like interacting pincer-like +++
with G4
uUNA pincer-like upwards pincer-like –
T12 aUNA downwards sideways interacting –
with G4
spacer-C3 interacting sideways nil –
with G4
uUNA interacting sideways interacting —
with G4 with G4
A reduction of up to 50% of anti-thrombin activity (CT50) is indicated by
(–), and reduction up to 75% is marked (—); a significant increase is de-
noted by (+++).
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of the TGT loop was affected. Similar to the data obtained for
the spacer-C3 variants, UNA variants TBA-U3 and TBA-U12 also
showed the loss of the T3, T9 and T12 orientations. Interesting-
ly, the structure of TBA-U7 was very similar to the unmodified
TBA, although not identical.
All TBA derivatives shown in Table 1 were used for the prime
molecular mechanics–generalised Born surface area (MM-
GBSA)-based binding affinity calculations. CT50 values were
compared with binding energies obtained from the MM-GBSA
calculations. The summary of the free energies obtained for
each complex is provided in Table S1, which shows all the
energy terms of Equation (1) together with the experimentally
measured activities, as well as the predicted binding free ener-
gies (DGbind). TBA-SP7, which had high potency (CT50=168 s)
among the compounds tested, was correctly predicted as a
highly stable compound by the MM-GBSA method
(@224.96 kcalmol@1). The coulomb energy for all of the com-
pounds, obtained by the MM-GBSA method, is highly favoura-
ble compared to the overall binding energy; however, signifi-
cantly high solvation energy (Esolvation) compensates for the
electrostatic contribution to the overall binding process. As
a result, the van der Waals (vdW) energy dominates the overall
binding affinity for all the compounds. It is important to em-
phasise that the covalent binding energy (Ecovalent) contribution
to the overall binding affinity of each complex is either negligi-
ble or unfavourable, except for the TBA-SP7 complex. In the
case of the TBA-SP7–thrombin complex, the covalent binding
energy contribution is remarkably low (@165.4 kcalmol@1),
compared to rest of the compounds in this series, and points
to this contribution as key to making TBA-SP7 the most ther-
mostable compound among those tested with respect to
thrombin binding (Figure S3). The covalent binding energy
was calculated from the energy difference between the throm-
bin-bound and free conformations of aptamer and essentially
refers to the contributions due to changes in intramolecular
structure of aptamer upon binding to thrombin. In the case of
TBA-SP7, the covalent binding energy was as much as
@165.4 kcalmol@1 and stabilises the thrombin:aptamer associa-
tion to larger extent. The energy of the aptamer was relatively
low when it was bound to thrombin compared to the confor-
mation of aptamer existing in solvent (comparison of Ecovalent
and DGcovalent is provided in Figure S4A in the Supporting Infor-
mation). We further analysed the data in order to understand
the covalent energy contribution and found no correlation
(R2=0.03) when DGcovalent was excluded from DGbind in the da-
taset. This effect was mainly due to the TBA-SP7 construct,
which behaved as an outlier ; however, when TBA-SP7 and TBA
were excluded from the dataset, the correlation improved to
R2=0.82 (Figure S4B). This analysis clearly indicated that the
high stability of TBA-SP7 was mainly due to the DGcovalent
energy, which also influenced the overall binding process to
thrombin.
In addition to prime MM-GBSA calculations, an additional ex-
tensive molecular dynamics simulation with explicit solvation
was performed for the highly active construct, TBA-SP7, in
order to compare the binding mode with TBA (wild-type) with
respect to binding free energies. Based on the 15 ns simula-
tions, the relative binding energies of TBA and TBA-SP7 in
thrombin were estimated. From Figure 3, it is clear that TBA-
SP7 binds (DGbind=@57.19:0.2) relatively more strongly than
TBA (DGbind=@38.26:0.3) in the thrombin binding site. An
individual energy contributions plot also reveals that nonpolar
contribution dominates the binding, as TBA-SP7 showed signif-
icantly higher EvdW and Esurf values compared toTBA.
Discussion
Data obtained from CD measurements clearly showed that the
introduction of amino-UNA, UNA or spacer-C3 modifications in
place of the thymidine nucleotide at positions T3, T7 and T12
was compatible with quadruplex formation, resulting in a simi-
lar structural topology to that of unmodified TBA. The appear-
ance of an absorption minimum at 265 nm and a maximum at
295 nm has been reported as characteristic for an antiparallel
single-stranded G-quadruplex topology and corresponds to
Figure 3. Comparison of different energy contributions for TBA and TPA-SP7
thrombin binding from extensive MD simulation-based MM-GBSA calcula-
tion: A) van der Waals energy, B) electrostatic (Ele) energy and solvation
generalized Born (GB), C) surface area energy—nonpolar energy, D) binding
energy and E) decomposition of binding energy. All energy components
were extracted from the differences (average) of DGcomplex@DGthrombin@
DGaptamer. Some residues were removed from the plot (E), due to an insignifi-
cant energy contribution (<0.1 kcalmol@1).
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the reported structure of TBA. Thus, all modified TBA sequen-
ces listed in Table 1 adapt the antiparallel chair-like G-quadru-
plex.
Next, UV melting studies were initiated to analyse the ther-
mal stability of the TBA derivatives. Notably, UNA or spacer-C3
substitution at T3, T7 or T12 increased the thermal denatura-
tion temperature, whereas the temperature decreased in the
case of amino-UNA modifications. This could possibly be ex-
plained by the influence on the G-quadruplex structure of the
2’–5’ internucleotide linkage between the sugar and the phos-
phate group or the 3’-amino group. As amino-UNA is a novel
construct, there are no studies that can be used to explain this
phenomenon directly. However, a recent study by Aher et al.
investigated the impact of 2’–5’-phosphodiester linkages and
loop lengths on the folding topology of TBA.[21] They showed
that all variants with a 2’–5’-linkage exhibited decreased melt-
ing temperatures. This effect was attributed to an increased
number of bonds between the 5’-O and 3’-O-phosphorus or/
and an extended backbone geometry enabled by the 2’–5’
linkage. Even though amino-UNA differs from the 3’-deoxy-2’–
5’-linked non-genetic isoDNA studied by Aher et al. , it seems
plausible that the decreases in melting temperatures that we
observed might be the result of a similar effect.
UNA and spacer-C3 are less rigid than normal nucleotides
and add more flexibility in the region in which they are intro-
duced. The loop regions are known to make contributions to
the stability of the G-quadruplex due to p-stacking between
loop nucleobases and G-quartets. Our data suggest that the
increased flexibility of the loop regions might have led to the
improved ability of loop nucleobases to interact with the G-
quartets, therefore resulting in enhanced thermal stability.[14]
For a better overview, the impact of modifying the TT loops
and the TGT loop on thrombin clotting times are discussed
separately:
TT loops modification
Modification of the thymine residues at positions 3 and 12
lead to a reduction in the inhibitory effect, which was ob-
served in the thrombin clotting experiments for all variants
(amino-UNA, spacer-C3 and UNA). Krauss et al. showed that the
two loops act as a pincer-like system that binds the protruding
region of thrombin exosite I.[10,11] Thus, the lack of thrombin in-
hibition of TBA-SP3 and TBA-SP12 is to be expected, as these
oligonucleotides no longer possess the crucial thymines that
facilitate the pincer formation. This is supported by our model-
ling results, which suggested that the substitution of either T3
or T12 with spacer-C3 led to profound structural rearrange-
ments, affecting the formation of a pincer-like structure (Fig-
ure S2D and F). Although they interact with the guanine
tetrad, these modifications are no longer available for interac-
tions with thrombin. This could explain not only the lack of in-
hibitory efficacy for both variants TBA-SP3 and TBA-SP12 but
also the increase in thermal stability as p-stacking interactions
of either T3 or T12 with the guanine tetrads that could in-
crease the stability of the structural core. For TBA-A3 and TBA-
A12, as well as for TBA-U3 and TBA-U12, our modelling data
suggested a similar change in structure (Figure S2A, C, G and
I). Even though the UNA and amino-UNA variants still have the
thymine residues at the modification site, it could be theorised
that the flexibility of these nucleotides induce stabilisation of
the G-quadruplex through a higher stacking energy with the
quartet. Consequently, this could result in a higher energy bar-
rier to form the pincer-like structure, which could negatively
affect TBA and collectively account for its reduced activity to-
wards thrombin.
In regard to the modification with amino-UNA, additional ex-
planations could be found. Recently reported crystal structures
showed that residues in the TT loop interact with two hydro-
phobic clefts of the anion-binding exosite I of thrombin
(ABE1).[10,11] The substitutions of these loop residues (T3 and
T12) with an amino-UNA led to the introduction of a polar
amino group. Thus, the hydrophobic interactions between the
loop regions and thrombin could be reduced, resulting in a de-
creased inhibitory effect. Furthermore, reduction in the inhibi-
tory ability of TBA-A3, TBA-A7 and TBA-A12 could be the result
of the observed lack of stability. Finally, results from the incor-
poration of UNA into TBA at positions T3 and T12 were in
agreement with the work of Pasternak et al. , who have previ-
ously reported that UNA incorporation at T7 (TBA-U7) in-
creased thrombin inhibition in anti-thrombin assays by using
blood plasma samples, whereas UNA incorporation at positions
T3 and T12 (TBA-U3 and TBA-U12) reduced the effect.[14]
TGT loop modification
The thrombin clotting time assay showed significantly pro-
longed clotting times for the variant TBA-SP7, whereas TBA-A7
and TBA-U7 failed to show high thrombin inhibition. Only mar-
ginal interactions of thrombin with the TGT loop of TBA were
reported by Krauss et al.[10] Additionally, He et al. reported the
relevance of the phosphate groups for the TBA–thrombin in-
teraction.[22] In regard to these reports, an explanation for the
reduced inhibition could be found in the amino group of
amino-UNA, as this group could have a steric influence on
these interactions in TBA-A7. However, it was also suggested
that the stability and rigidity of TBA is important for the inter-
action between aptamer and thrombin exosite I.[16] As the var-
iants with amino-UNA exhibited the lowest melting tempera-
tures of all tested variants, including TBA, this could also be an
explanation for the reduced inhibitory effect of the amino-UNA
variants. In contrast, the spacer-C3 variant is expected to exhib-
it the pincer-like structure while also exhibiting increased sta-
bility; collectively this could account for the improved efficacy
for TBA-SP7 in the thrombin clotting time assay. It is worth
mentioning that, for a direct comparison, the buffer condition
must be the same in all above-mentioned assay; however, we
adopted the suggested buffer system reported by a previous
group,[14] which only allows for comparison between the un-
modified TBA and the modified TBAs discussed here.
For TBA-U7, our results deviate from the published data by
Pasternak et al.[14] They reported that UNA incorporation at T7
(TBA-U7) increased the thrombin inhibition in anti-thrombin
assays using blood plasma samples. The different assays for
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measuring the effect of TBA derivatives on thrombin activity
can be taken as a basis for this discrepancy. The thrombin clot-
ting time assay measured the effect of TBA on thrombin in
PBS, whereas the anti-thrombin assay measured the activity in
human plasma in which other plasma components could inter-
act with thrombin and decrease the concentration available for
thrombin interaction. Likewise, interactions with these other
plasma components could destabilise the structure of TBA.
Thus more stable forms, like TBA-U7, could exhibit superior
inhibitory activity in plasma, while being inferior in a buffer
system like PBS. Another explanation for this discrepancy can
be found in the different TBA concentrations used (50 nm of
TBA-U7 used in this study compared to 330 nm used by Paster-
nak et al.). Earlier studies have already shown that the concen-
tration strongly affects the inhibitory capability of the TBA
aptamer.[23,24] These discrepancies highlight the importance of
testing modified aptamers in various settings in order to grasp
possible drawbacks of prior in vivo and preclinical investiga-
tions.
Although electrostatic interactions contributed favourably to
the overall binding of TBA, very highly unfavourable solvation
energy compensated for the electrostatic energy, and as a re-
sult, nonpolar interactions such as vdW and lipophilic energies
dominate the overall binding energy of these analogues (Fig-
ure S5). In general, amino-UNA analogues bound with moder-
ate affinity to thrombin (CT50 ranges from 45 to 55). From the
binding affinity calculation, TBA-SP3 (DG=@46.5 kcalmol@1)
and TBA-SP12 (DG=@57.7 kcalmol@1) should bind poorly to
thrombin as compared to TBA-SP7 (DG=@225.0 kcalmol@1),
and this could be mainly due the loss of crucial interactions at
the interface between the TBA-SP3 analogue and residues at
the thrombin active site, for example, Tyr117, Asn78 and Ile79
with T3 and Thr74, Arg75 and Tyr76 with T12. Moreover, non-
polar interactions (EvdW=@58.1 kcalmol@1) were significantly fa-
vourable for binding with thrombin (Table S1) as compared to
rest of the analogues. It was clearly seen that TBA-U7 binds
significantly better than TBA-U3 and TBA-U12. Again, this
might be due to the effect of interaction with thrombin resi-
dues. When positions T3 and T12 were modified with uUNA
nucleotide, interactions between residues such as Thr74,
Arg75, Tyr76, Asn78, Ile79 and Tyr117 with T3/T12 were lost.
This is also significantly reflected in the overall binding affinity
of U3 (DG=@33.5 kcalmol@1) and U12 (DG=@30 kcalmol@1)
compared to U7 (DG=@65.7 kcalmol@1). We note from individ-
ual energy components contributions to the overall binding
affinity that the value of EvdW was quite low for U3 (@6.4 kcal
mol@1) and U12 (@51.7 kcalmol@1) compared to that of U7
(@75.0 kcalmol@1).
In addition, we also performed combined molecular dynam-
ics (to account for sampling effects at particular temperatures)
and MM-GBSA calculations to compute the binding free
energy for TBA and TBA-SP7 to thrombin. Both van de Waals
and surface area energies in the binding energy clearly
showed that nonpolar contribution is the main driving force to
discriminate the TBA-SP7 from TBA binding to thrombin
(Figure 3). Energy decomposition analysis from free energy cal-
culation examines the role of individual residue contributions
to the overall binding affinity of the aptamers by decomposi-
tion of the binding free energy into aptamer–residue pairs. As
seen from the decomposition analysis plot (Figure 3E), TBA-
SP7 showed relatively different interaction patterns than TBA
with thrombin residues during the simulation. For instance,
residues Asp63, Arg75, Arg77_A, Asn78, Ile79 and Tyr117
showed a favourable energy contribution (&2.00 Kcal mol@1
difference) to the binding affinity of TBA-SP7 compared to
TBA, especially Tyr117, which showed an additional energy
contribution for TBA-SP7 (@2.25 kcalmol@1) and whereas for
TBA, this residue contributed very low (0.004 kcalmol@1). More-
over, some residues from the aptamer also equally contributed
to the overall binding affinity of the complex as thrombin resi-
dues, for instance, T3, T4, G5, T12 and T13 resides. These apta-
mer–thrombin structural interaction observations are also in
good agreement with Prime MM-GBSA calculations. Analysis
from the backbone RMSD and radius of gyration also suggest-
ed that the TBA-SP7–thrombin complex was relatively more
stable than the TBA–thrombin complex (Figure S6); in particu-
lar, when it was bound to thrombin, the overall RMSD re-
mained less than 2.0 a, whereas the thrombin–TBA complex
was quite flexible throughout the simulation. In addition, the
radius of gyration (of the Ca atoms) of aptamers (TBA and
TBA-SP7) from simulations was also computed and compared
to the initial pose in order to provide a measure of overall
compactness of molecular shape of aptamers.[25–27] As seen
from Figure S6B, the overall molecular shape of TBA-SP7 looks
very similar to TBA when the aptamer binds to the thrombin.
Another recent report[28] showed the TBA structural stability
and flexibility by using the static modes (SM) calculation in-
cluding polythymines, PEG spacers and alkyl chain modifica-
tions in the TBA. We concluded that the introduction of
spacers in the aptamer greatly affects not only the structural
stability of TBA but also its ability to position itself within
thrombin exosite I. Our observations, based on the MM-GBSA
calculations, also suggest that overall structural stability of
aptamer–thrombin is not only governed by electrostatic
energy (provides internal stability of aptamers) but also non-
polar interactions, especially van der Waals and surface area
energy complementarity, which is essential for aptamers bind-
ing to the thrombin exosite I. This observation led us to be-
lieve that this is another demonstration of the malleability of
G-quadruplex-forming aptamers, as previously observed for
other aptamers.[28,29]
Conclusion
In summary, we have systematically investigated the impor-
tance of the flexibility of TBA loops by incorporating three dif-
ferent chemical modifications: spacer-C3, amino-UNA and UNA.
All three modifications rendered high flexibility and less rigidity
to TBA compared to natural nucleotide monomers, and this in-
creased flexibility favoured stronger interactions of the nucleo-
base with the guanine tetrads, resulting in quadruplex forma-
tion with high thermal stability. In addition, the flexibility possi-
bly favoured structural rearrangements of TBA-type sequences,
especially towards the pincer-like structure of the TT loops and
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the orientation of T9. Unlike amino-UNA- and UNA-modified
TBA sequences, one introduction of spacer-C3 at position T7 of
the TGT loop showed significant improvement in thermal sta-
bility and thrombin clotting time compared to unmodified TBA
while maintaining the G-quadruplex structure. We believe that
these findings will be very useful in designing next-generation
thrombin-binding aptamers.
Experimental Section
Oligonucleotide synthesis: All oligonucleotides were synthesised
by using standard phosphoramidite chemistry on an automated
oligonucleotide synthesiser. All synthesised oligonucleotides were
purified by ion exchange HPLC, and their composition was con-
firmed by MALDI-TOF mass spectrometry. Synthesis of oligonucleo-
tide sequences containing the 3’-amino-UNA-U nucleotide mono-
mer has not been reported elsewhere. Towards the construction of
these novel oligonucleotide sequences with an oligonucleotide
synthesiser, the synthesis methodology for 3’-amino-UNA-U nucleo-
side phosphoramidite derivative (4, Scheme 3) is briefly described
below.
Synthesis of amino-UNA-U phosphoramidite: Compound 1
(Scheme 3) was treated with methanesulfonyl chloride in pyridine
to activate the alcohol. The crude mesylate was converted into an
azide by dissolving it in acetonitrile and reacting it with sodium
azide and 15-crown-5 ether in a microwave reactor. The benzoyl
protecting group was removed by hydrolysis with sodium hydrox-
ide in methanol. The final reduction of the deprotected azide was
achieved under Staudinger conditions by employing trimethyl-
phosphine as the reducing agent in a mixture of tetrahydrofuran
and water, obtaining the desired 3’-amino UNA-U phosphoramidite
in 62% yield over four steps. The free amine was protected by
using ethyl trifluoroacetate in MeOH with dimethylaminopyridine
(DMAP) as a nucleophilic catalyst. The final amidite was furnished
from 2-cyanoethyl N,N,N’,N’-tetraisopropyldiamidophosphite and
diisopropylammonium tetrazolide in dichloromethane (detailed
procedures are provided in the Supporting Information).
Melting temperature studies: Melting temperatures were record-
ed on a Beckman DU800 spectrophotometer equipped with a six-
position microcell holder and a thermostat. Oligonucleotides
(12.5 mm final concentration) were dissolved in buffer containing
potassium chloride (100 mm) and sodium cacodylate (10 mm),
pH 7. The samples were renatured for 10 min at 95 8C and then
slowly cooled to room temperature. Absorbance versus tempera-
ture curves in 10 mm quartz microcuvettes were recorded at
295 nm. A temperature range of 15–85 8C was used at 0.5 8Cmin@1.
Three spectra were recorded and averaged for each sample. The
spectrum for buffer only (no sample added) was subtracted from
each sample spectrum. Melting curves were analysed by using
nonlinear curve fitting with the program MeltWin 3.5.[30]
Circular dichroism (CD) spectra: CD spectra were recorded on
a Jasco J-600A spectropolarimeter by using a 0.7 mL quartz cuvette
with a 2 mm path length. Oligonucleotides (2.5 mm final concentra-
tion) were dissolved in phosphate buffer (10 mm, pH 6.9) contain-
ing KCl (5 mm). All samples were renatured for 10 min at 80 8C and
then slowly cooled to room temperature prior to measurement at
15 8C with a 220–320 nm wavelength range. Five spectra were re-
corded and averaged for each sample. The buffer spectrum was
subtracted from each sample spectrum.
Thrombin clotting time assay: Thrombin clotting times were mea-
sured spectrophotometrically on a PerkinElmer Lambda 35 UV/Vis
spectrometer. Oligonucleotides were incubated for 1 min at 37 8C
in PBS (1 mL) containing fibrinogen from human plasma
(2 mgmL@1, F 3889, Sigma–Aldrich). Then, human thrombin
(100 mL, 10 NIH per mL; T8885, Sigma–Aldrich) was added to the
solution. The time required for fibrin polymerisation was deter-
mined from the UV scattering curve, which was registered as
a function of time (wavelength fixed at 380 nm; total time: 600 s;
time interval: 0.1 s) for each sequence. Each measurement was per-
formed in triplicate at 50 nm concentrations of each oligonucleo-
tide. The clotting time value, reported as average: standard devia-
tion (AV.:S.D.) was derived from the midpoint of each scattering
curve. This corresponded to the time at which 50% of the final ab-
sorbance was observed.
Scheme 3. Synthesis of 3’-amino-UNA-U nucleotide phosphoramidite. I) MsCl, anh. pyridine, 2 h, RT; II) NaN3, 15-crown-5, MeCN, 30 min, 130 8C in MW reactor;
III) 0.1m NaOH, MeOH, 16 h, RT; IV) Me3P, THF/H2O, 16 h, RT (62% over four steps) ; V) ethyl trifluoroacetate, DMAP, MeOH, 2 h, RT (94%); VI) 2-cyanoethyl
N,N,N’,N’-tetraisopropyldiamidophosphite, diisopropylammonium tetrazolide, CH2Cl2, 5–16 h, RT (81%).
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Computational modelling
Preparation of aptamers and protein : The molecular structure of
the human thrombin–aptamer (TBA) complex was obtained from
the Protein Data Bank (PDB ID: 4DII, 2.06 a resolution).[10] The TBA
was imported into the Maestro module available in the Schrçding-
er Suite (Schrçdinger, LLC), and subsequently, the atomic coordi-
nates of the aptamer were separated from the thrombin coordi-
nates, and both were optimised separately. The thrombin structure
was optimised by using the Protein Preparation Wizard.[31] This pro-
tein structure optimisation includes adding hydrogen atoms, as-
signing bond orders and building disulfide bonds. The protonation
states of the ionisable residues (pH 7) were predicted by the
PROPKA tool provided in the Protein Preparation Wizard. An opti-
mised structure model was finally found by energy minimisation
(i.e. , position of the hydrogen atoms) with the OPLS2005 force
field.
For the aptamer, the protonation states were predicted by using
the PROPKA tool in the presence of a K+ ion. Finally, the structure
was energy-minimised (only hydrogen atoms) by using the
OPLS2005 force field. The structures of TBA derivatives (amino-
UNA, spacer-C3 and UNA) used in these experiments were built
manually by using the Maestro module available in the Schrçding-
er Suite from an optimised aptamer obtained from the X-ray crystal
structure.[10] TBA derivatives were energy-minimised to avoid any
unfavourable contacts or steric clashes between the atoms. Subse-
quently, optimised structures were used for conformational analy-
sis and MM-GBSA-based binding affinity prediction calculations.
Conformational analysis: In order to reveal the structural stability
of various TBA derivatives, we initiated short stochastic dynamic
simulations on these modified TBAs by using the Macro Model
(version 9.1), as it is implemented in the Schrçdinger Suite. All cal-
culations were carried out by using the AMBER* force field[32] with
a GB/SA solvation model.[33] In the process of thermalisation, initial
velocities were generated from a Maxwell–Boltzmann distribution
at 300 K. The SHAKE algorithm was utilised to constrain the lengths
of all bonds involving hydrogen atoms. Coordinates were saved
every 1.5 fs from the 0.5 ns simulation for the analysis. For minimi-
sation, the PRCG (Polak–Ribiere Conjugate Gradient) protocol was
applied with a convergence threshold of 0.05 kJmol@1. Representa-
tive low-energy structures for each TBA derivative were selected
for further inspection.
MM-GBSA calculations: In order to understand the binding affinity
differences of various TBA complexes, MM-GBSA calculations were
initiated by using the Schrçdinger Suite (Prime MM-GBSA).[34,35]
MM-GBSA method implementation in the Schrçdinger Suite is
slightly different from the corresponding MM-PBSA method de-
scribed in our previous work.[29] Whereas the MM-PBSA method is
based on molecular dynamics simulations, the Prime MM-GBSA
method calculates the binding affinity of the aptamer (DGbind) by
energy minimisation procedures. The binding energy of the apta-
mer was extracted from an energy-optimised thrombin–aptamer
complex and Prime MM-GBSA by using the VSGB 2.0 solvation (im-
plicit) model.[33] The Prime MM-GBSA energy of the aptamer bind-
ing is estimated as [Eq. (1)]:
DGbind ¼ Ecomplex@ Ethrombin@ Eaptamer ð1Þ
This procedure is very efficient and is frequently used to rank pro-
tein–ligand complexes in the virtual screening process of lead
identification/optimisation. During binding affinity prediction, the
program offers the option to treat the aptamer and protein as flex-
ible; in this study, a 5.0 a region of the protein around the ligand
was treated as flexible.
Extensive molecular dynamic simulations (eMD): Molecular dynam-
ics (MD) simulations were carried out for the two chosen throm-
bin–aptamer complexes, namely thrombin:TBA (wild-type) and
thrombin:TBA-SP7. The starting structure for the thrombin:TBA
used in the MD simulation is based on the structure reported in
the Protein Data Bank (PDB ID: 4DII).[10] The starting structure for
thrombin:TBA-SP7 was obtained by modifying residue 7 (DT7) of
the aptamer with a spacer group (-CH2-CH2-CH2-), and this struc-
ture was relaxed by using the AMBER force field.[36] Both complexes
were solvated in water and neutralised with a sufficient number of
counter ions (seven Na+ ions). The K+ ion stabilising the aptamer
geometry was also retained in both of the thrombin–aptamer com-
plexes. The simulation box was chosen as orthorhombic and con-
tained more than 20000 water molecules. The force field for de-
scribing the aptamer and thrombin was FF99SB,[37] as it contains
parameters for both amino acids and nucleic acids, which are the
fundamental units of proteins and DNA/aptamers, respectively. The
water solvent was described by using the TIP3P force field. The
space group parameters were based on general AMBER force field
(GAFF), and the charges for this nonstandard residue were pre-
pared based on fitting to the molecular electrostatic potential ob-
tained by employing the Merz–Singh–Kollman Scheme.[38] Struc-
tures were optimised with the HF/6-31G* level of theory, as imple-
mented in Gaussian09.[39]This protocol is often employed to de-
scribe any nonstandard residue or organic molecule in force field
MD simulations. The solvated complexes were first energy-mini-
mised, then the simulations were carried out under constant tem-
perature and pressure (room temperature, 1 atm pressure). The
temperature was controlled by using a Langevin thermostat;[40] the
pressure was controlled by connecting the systems to a Berend-
sen’s barostat.[41] The time scale for integration of equation of
motion was 2 fs. The initial timescale for the equilibration of the
systems was 2 ns, and the total production run was 15 ns. The cal-
culations were carried out by using Amber14 software.[42]The time
evolution of total energies and system densities served as indica-
tors for the equilibration runs. Further, the stability of both apta-
mer–thrombin complexes was verified by the potential energy
landscape, root mean square displacement (RSMD) and radius of
gyration. Free-energy calculations (from 400 configurations), the
RMSD and the radius of gyration analysis were performed for the
last 5 ns trajectory of the production run. The MMPBSA.py tool[43]
of the Amber software was employed for this purpose. Various
contributions to the total binding free energy, namely vdW, elec-
trostatic, polar solvation and nonpolar solvation-free energies were
obtained, and the results are presented in Table ST2. The entropy
calculations were also performed by using normal mode analysis
(for 50 configurations collected at equal intervals from the last 2 ns
run). The binding free energy analysis showed that the thrombin–
TBA-SP7 made a stronger complex than the thrombin–TBA (wild-
type) complex itself. The reason for this was analysed by using de-
composition analysis, in which the individual residue contributions
to total binding free energy can be computed.
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